Purchase this article with an account.
K. Kim, J. Kim, K. Kim, Y. Yu, J. Kim; Intravenously Administrated Anti-Recoverin Antibody Does Not Pass Through Blood Retinal Barrier. Invest. Ophthalmol. Vis. Sci. 2010;51(13):837.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate whether intravenously administrated anti-recoverin antibodies could pass through blood-retinal barrier (BRB) and lead to retinal cell death.
The anti-recoverin antibody was intravenously injected via tail vein and the eye was enucleated after 1 day and 7 days. To induce BRB disruption, vascular endothelial growth factor (VEGF) was injected into the intravitreal cavity, which was confirmed by fluorescein angiography with fluorescein-conjugated dextran. Immunofluorescence staining for recoverin, CD31 and glial fibrillary acidic protein (GFAP) as well as TUNEL was performed. Western blot analysis for occluding and ZO-1/2 was performed.
Intravenously administrated anti-recoverin antibodies were exclusively distributed on retinal vessels which were co-localized with CD31, and led to neither increase of GFAP expression, as an indicator of retinal stress, nor apoptotic retinal cell death. Moreover, even in the condition of VEGF-induced BRB breakdown, anti-recoverin antibodies could not migrate across BRB and still remained on retinal vessels without retinal cytotoxicity.
Our results suggest that high titer of intravascular anti-recoverin antibodies could not penetrate into the retina by themselves, and BRB breakdown mediated by dysregulation of tight junction might not be sufficient to allow anti-recoverin antibodies to pass through BRB.
This PDF is available to Subscribers Only